- Report
- November 2025
- 474 Pages
Global
From €5270EUR$5,850USD£4,650GBP
- Report
- November 2025
- 285 Pages
Global
From €5270EUR$5,850USD£4,650GBP
- Report
- November 2025
- 373 Pages
Global
From €5270EUR$5,850USD£4,650GBP
- Report
- November 2025
- 194 Pages
Global
From €5270EUR$5,850USD£4,650GBP
- Report
- September 2025
- 250 Pages
Global
From €4045EUR$4,490USD£3,569GBP
- Report
- April 2025
Global
From €4414EUR$4,900USD£3,895GBP
- Report
- April 2025
- 150 Pages
Global
From €3468EUR$3,850USD£3,060GBP
€4369EUR$4,850USD£3,855GBP
- Report
- July 2025
- 226 Pages
Global
From €4008EUR$4,450USD£3,537GBP
- Report
- August 2025
- 150 Pages
Global
From €3468EUR$3,850USD£3,060GBP
- Report
- March 2025
- 150 Pages
Global
From €3468EUR$3,850USD£3,060GBP
€4369EUR$4,850USD£3,855GBP
- Report
- July 2025
- 82 Pages
Global
From €3500EUR$4,162USD£3,196GBP
- Report
- July 2025
- 112 Pages
Global
From €3500EUR$4,162USD£3,196GBP
- Report
- August 2025
- 115 Pages
Global
From €13507EUR$14,995USD£11,918GBP
- Report
- January 2025
- 88 Pages
North America
From €3108EUR$3,450USD£2,742GBP
- Report
- August 2023
- 115 Pages
Global
From €2027EUR$2,250USD£1,788GBP
- Report
- January 2024
- 200 Pages
Global
From €3738EUR$4,150USD£3,298GBP
- Report
- January 2024
- 200 Pages
Global
From €3738EUR$4,150USD£3,298GBP
- Report
- October 2024
- 200 Pages
Global
From €3378EUR$3,750USD£2,981GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2702EUR$3,000USD£2,384GBP
€3378EUR$3,750USD£2,981GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €2702EUR$3,000USD£2,384GBP
€3378EUR$3,750USD£2,981GBP

The Respiratory Syncytial Virus (RSV) Vaccine is a type of respiratory drug used to prevent infection from the RSV virus. It is typically administered to infants and young children, as well as to adults who are at high risk of developing severe RSV infection. The vaccine works by stimulating the body’s immune system to produce antibodies that can fight off the virus. It is usually given in two doses, with the second dose given one month after the first.
The RSV Vaccine market is a growing sector of the respiratory drugs market. It is estimated that the global RSV Vaccine market will reach a value of over $1 billion by 2025. The market is driven by increasing awareness of the virus and its potential to cause severe illness, as well as the development of new vaccines.
Some of the major companies in the RSV Vaccine market include GlaxoSmithKline, Merck, Pfizer, Sanofi, and Novavax. Show Less Read more